We developed and benchmarked several aptamers built from nucleic acid and peptide oligomers that specifically recognize autoantibodies in RA and SLE patients. Importantly, our new aptamers have a potential to effectively predict disease flares, which is not possible using current technology. Flare prediction is crucial for managing SLE and RA patients, in order to avoid rapid disease progression and in some cases death.